Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases

Last updated: August 21, 2023
Sponsor: University Hospital, Basel, Switzerland
Overall Status: Active - Recruiting

Phase

N/A

Condition

Allergy

Rash

Treatment

Analysis of samples

Clinical Study ID

NCT05732987
2020-02645; sp19Navarini3
  • Ages 18-100
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This study is to identify rare, disease-causing mutations of several rare neutrophil dermatoses. To identify associations between NMID and variants in the genome next generation sequencing, mainly whole exome sequencing, will be used. In a second approach the expression level of already known inflammatory proteins in skin samples will be investigated.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • written consent of the participating person

  • diagnosis of a disease in the NMID form group or proband of the control group

Exclusion Criteria for patients:

  • Missing informed consent if samples collected after 2014

  • no diagnosis of NMID

Exclusion Criteria for healthy controls:

  • Missing informed consent

Study Design

Total Participants: 3370
Treatment Group(s): 1
Primary Treatment: Analysis of samples
Phase:
Study Start date:
February 03, 2023
Estimated Completion Date:
September 30, 2029

Study Description

The origin of rare severe inflammatory skin diseases in dermatology is insufficiently known. They have in common the presence and activation of phagocytes, affect the quality of life through pain and inflammation and disfiguration, and can even be fatal. This study is intended to build on the findings that several of these neutrophil-mediated inflammatory dermatoses (NMID) have a genetic background and to identify rare, disease-causing mutations of several rare neutrophil dermatoses. This non-clinical case-control study is a research project with biological material and health-related data. To identify associations between NMID and variants in the genome next generation sequencing, mainly whole exome sequencing, will be used. In a second approach the expression level of already known inflammatory proteins in skin samples will be investigated. The data are obtained and verified using standardized methods as e.g. Nanostring, RNA sequencing and qRT-polymerase chain reaction (PCR), proteomics assays and immunohistochemistry as well as flow cytometry and imaging mass cytometry, ELISA, and Western Blot.

Connect with a study center

  • University Hospital Basel, Clinic of Dermatology

    Basel, 4031
    Switzerland

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.